Immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: Intravenous versus subcutaneous administration

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired sensory-motor neuropathy with autoimmune pathogenesis. First line treatments include corticosteroids, plasmapheresis, and immunoglobulin therapy. The classic form of immunoglobulin administration is intravenous, however subcutaneous immunoglobulin (SCIG) therapy became a valid alternative option especially for maintenance therapy. Cross-sectional study to compare long-term response to intravenous immunoglobulin (IVIG) and SCIG.